{"id":"W2907026589","doi":"10.1055/s-0038-1675816","title":"The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations","year":2018,"lang":"en","type":"review","venue":"Thrombosis and Haemostasis","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute; McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Hamilton Health Sciences Foundation; National Institute for Health and Care Research; McMaster University; Hamilton Health Sciences; Heart and Stroke Foundation of Canada","keywords":"Rivaroxaban; Apixaban; Edoxaban; Dabigatran; Medicine; Vitamin K antagonist; Warfarin; Direct thrombin inhibitor; Intensive care medicine; Clinical trial; Stroke (engine); Dosing; Anticoagulant; Atrial fibrillation; Pharmacology; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001880648,0.0007152976,0.0007700436,0.001469814,0.0008534823,0.002354847,0.0007521033,0.003080031,0.008629186],"category_scores_gemma":[0.007017183,0.0003368155,0.0006861845,0.0008684873,0.001627338,0.002461072,0.001507852,0.003495562,0.004997087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001096088,"about_ca_system_score_gemma":0.003247116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001686889,"about_ca_topic_score_gemma":0.002966465,"domain_scores_codex":[0.9986349,0.0003088554,0.0003708404,0.0001398656,0.0004027012,0.0001428338],"domain_scores_gemma":[0.9940733,0.002352044,0.0008204656,0.0001917188,0.001826199,0.0007361061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000513519,0.00009009206,0.004093391,0.002137507,0.00002836541,0.001934245,0.0004778175,0.00021411,0.001080205,0.004129184,0.7021425,0.2836212],"study_design_scores_gemma":[0.00001676799,0.0001322908,0.003517585,0.00271873,0.00002716685,0.009997268,0.0003258432,0.0001399482,0.0003619975,0.003357417,0.9793822,0.00002274274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01092722,0.4178573,0.00939218,0.2505632,0.1988985,0.0005968568,0.0004846261,0.0005168963,0.1107632],"genre_scores_gemma":[0.04198422,0.4995188,0.009436468,0.1276843,0.2620199,0.0002942769,0.00116453,0.0002521865,0.05764544],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008629186,"threshold_uncertainty_score":0.02886748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1929602971005452,"score_gpt":0.4305789342408461,"score_spread":0.2376186371403009,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}